A Small Molecule Inhibitor of Enterocytic Microsomal Triglyceride Transfer Protein; SLx-4090, Biochemical, Pharmacodynamic, Pharmacokinetic and Safety Profile

Authors: Enoch Kim, Stewart Campbell, Olivier Schueller, Eric Wong, Bridget Cole, Jay Kuo, James Ellis, John Ferkany and Paul Sweetnam

Primary Laboratory of Origin:
Surface Logix, Inc.
50 Soldiers Field Place
Brighton, MA 02135

Affiliation:
EK, SC, OS, EW, BC, JK, JE, JWF, PS
Surface Logix, Inc.
50 Soldiers Field Place
Brighton, MA 02135
RUNNING TITLE PAGE

Running title: SLx-4090; an enterocytic specific MTP inhibitor

Corresponding author:

Paul Sweetnam, CSO
Surface Logix, Inc.
50 Soldiers Field Place
Brighton, MA 02135
617.746.8515 (office)
617.783.8866 (fax)
psweetnam@surfacelogix.com

Number of text pages: 25 (Introduction through Discussion)
Number of tables: 3
Number of figures: 7
Number of references: 34
Number of words:
  Abstract - 237
  Introduction - 724
  Discussion ~1767

Non-standard abbreviations:

ApoA1, apolipoproteinA1
ApoB, apolipoproteinB
ApoE−/−, apolipoproteinE deficient mice
DIO, diet induced obesity

Page 2 of 39
HDL-C, high density cholesterol
HFD, high fat diet
LC-MS/MS, liquid chromatography with tandem mass spectroscopy
LDL-C, low density cholesterol
LFD, low fat diet
LOQ, lower limit of quantitation
MC, methylcellulose
PD, pharmacodynamic
PK, pharmacokinetic
PP, postprandial
TG, triglycerides
VLDL-C, very low density cholesterol

Recommended section assignment:
Gastrointestinal, Hepatic, Pulmonary, and Renal
ABSTRACT

First generation microsomal triglyceride transfer protein (MTP) inhibitors were designed to inhibit hepatic MTP and provide a novel treatment of dyslipidemia. Effective at lowering LDL-cholesterol (LDL-C) these inhibitors also elevated liver enzymes and induced hepatic steatosis in animals and humans. MTP is highly expressed in the enterocytes lining the lumen of the jejunum and is critical in the production of chylomicrons assembled from lipid/cholesterol and their transfer into systemic circulation. SLx-4090 was designed to inhibit (IC$_{50}$ value $\sim$ 8 nM) only MTP localized to enterocytes. In Caco-2 cells SLx-4090 inhibited apolipoproteinB (ApoB; IC$_{50}$ value $\sim$ 9.6 nM) but not apolipoproteinA1 (ApoA1) secretion. Administered orally to rats SLx-4090 reduced postprandial (PP) lipids by $>50\%$ with an ED$_{50}$ value $\sim$ 7 mg/kg. SLx-4090 was not detected in the systemic or portal vein serum of animals (LOQ $\sim$ 5 ng/mL) following single or multiple oral doses in fasted rodents. When co-administered with tyloxapol, SLx-4090 did not inhibit the secretion of hepatic triglycerides (TG), consistent with absence of systemic exposure. Chronic treatment with SLx-4090 in mice maintained on high fat diet decreased LDL-C, TG and resulted in weight loss without elevation of liver enzymes or increase in hepatic fat. The compound did not result in toxicity when administered to rats for 90 days at a dose of 1000 mg/kg/day. These data support the concept that the inhibition of enterocytic MTP could serve as a useful strategy in the treatment of metabolic disorders.
INTRODUCTION

Impaired lipid metabolism (dyslipidemia) is considered a major contributor to the etiology of metabolic and cardiovascular disease (Ginsberg et al, 2009; Cannon, 2008). Dyslipidemia, broadly characterized by elevated circulating levels of LDL cholesterol (LDL-C) and triglycerides (TG), is commonly treated by therapeutic intervention at the level of hepatic function (Reiner, 2010).

Therapeutic response is determined by measurement of serum lipid levels while a patient is in a “fasting” state having not eaten for at least an overnight period. This measure, while useful due to its simplicity, is not representative of the changes in plasma lipid levels that most individuals experience throughout the day. In fact the consumption of multiple meals during the day creates a condition of metabolic flux commonly referred to as the postprandial (PP) state. The PP state is characterized by relatively prolonged spiking of TG-rich lipoproteins which occurs following the ingestion of each meal and it is this state that is truly representative of the human metabolic condition. Increases in serum TG-lipoproteins levels vary according to an individual’s metabolism as well as the content of their meals (Mattes, 2009). Therefore individuals have distinct basal PP profiles differing in the rate and amount of lipids that are absorbed. It has also been suggested that certain PP lipid patterns can not only exacerbate metabolic diseases but play a fundamental role in the development of the disease itself (Tushuizen et al., 2010; Phillips et al., 2006).

One strategy for the controlling circulating levels of LDL-C and TG is the inhibition of hepatic MTP. MTP plays a crucial role in the assembly of TG, cholesterol esters, and phospholipids into ApoB-containing lipoproteins and is integral in the assembly of very low density lipoprotein (VLDL-C) in the liver (Tietge et al., 1999). Initial discovery of small molecule inhibitors of MTP was thought to provide an alternative treatment for patients not at goal on statin therapy by reducing the hepatic production of VLDL-C. These efforts led to the discovery of molecules that were potent inhibitors of hepatic MTP and proved very effective in reducing the ability of the liver to export VLDL-C (Li et al, 2007; Aggarwal et
al, 2005; Chandler et al., 2003; Gruetzmann et al., 2000; Roevens et al., 1999; Wetterau et al., 1998). Unfortunately blockade of hepatic MTP was quickly associated with a significant decrease in the ability of the liver to rid itself of fat and administration of MTP inhibitors in clinical trials universally resulted in unacceptable rises in liver transaminases and increase hepatic fat disposition consistent with hepatic steatosis or “fatty liver” (Hussain and Bakillah, 2009; Lilly and Rader, 2007; Miyazaki et al., 2007; Lammens et al., 1999). The clinical development of molecules that inhibited hepatic MTP was essentially discontinued with respect to use across broad indications. The recent advancement of a traditional hepatic MTP inhibitor into clinical trials to assess the effectiveness of such treatment in a small genetic population of Type IV familial hyperlipoproteinemia has again confirmed the alarming increases in liver transaminases at extremely low doses (Samaha et al., 2008).

MTP is also found in the intestine and is critical in the transfer of TGs onto apolipoprotein B_{48} (ApoB) for subsequent transfer to the systemic circulation (Hussain and Bakillah, 2009; Gordon and Jamil, 2000). The development of agents that impact PP lipid levels by inhibiting only intestinal MTP may serve as the next generation of agents for the treatment of metabolic disorders.

Given the proven ability of small molecules to effectively inhibit MTP our approach was to design a drug that would inhibit the MTP found in the intestinal lining but would have no impact on the liver. This strategy required the design of a small molecule that interacted preferentially with the lipids that comprises the apical membrane of the enterocyte. Understanding the interaction of SLx-4090 with the plasma membrane lipids that comprise the extensive apical surface area of the enterocyte enabled controlled access and delivery to MTP found within this cell type.

SLx-4090 demonstrates all of the pharmacological and physiological properties of a potent inhibitor of MTP. Unlike earlier MTP inhibitors the compound is not systemically available and is not associated with hepatic toxicities. The ability to inhibit enterocytic, but not hepatic MTP, will make it possible to
pharmacologically isolate the intestine in order to better understand the PP state and its impact on the etiology of metabolic disease.
METHODS

**SLx-4090 and CP-346086 Synthesis.** The synthesis of SLx-4090 (Figure 1) is described fully in European Patent No. EP1877369 (Bartolozzi et al., 2008). CP-346086, a bioavailable MTP inhibitor first reported by Chandler et al. (2003) was synthesized at Surface Logix according to published methods (Chandler et al., 2003).

**Materials:** Caco-2 cells were purchased from ATCC (Rockville, MD). Pooled mixtures of human male microsomes purchased from Becton Dickinson (San Jose, CA) and InVitro Technologies (Baltimore, MD) were used as sources of MTP and for stability studies. Primary hepatocytes were purchased from CellzDirect (Carlsbad, CA) or InVitro Technologies and were prepared freshly from livers of male donors. Where tissues were donor human tissues all appropriate requirements concerning the use of human tissues were observed. DMEM, MEM, and fetal bovine serum were purchased from ATCC. ApoB and ApoA1 ELISA kits (AlerCheck; Portland, ME) were used according to the manufacturer’s instructions. Reagent grade chemicals were sourced from Sigma Aldrich and used as received. Sprague-Dawley rats were from Hilltop (Scottdale, PA); ApoE−/− animals were from Taconic Farms (Rockville, MD). All animals were fed standard rodent chow (low fat diet (LFD); 15.7 % calories from fat; 5.3 % fat by weight; Harlan) ad libitum unless otherwise indicated. Where animals were maintained on a high fat diet (HFD) the chow was Teklad TD.88137 (Harlan), with 42% calories from fat (21 % by weight).

LFD and HFD chows containing SLx-4090 as an admix were manufactured under contract by Harlan Laboratories.

**Inhibition of MTP Activity In Vitro.** The TG transfer assay for MTP activity was based on the protocol described previously (Chandler et al., 2003) using human liver microsomes containing active MTP. Microsomes from male donors were pooled prior to use. The potency of compounds as inhibitors...
of MTP was determined by fluorometry using a kit from Chylos (Woodbury, NY) that contained pre-assembled donor and acceptor lipid-vesicles.

**Caco-2 Cell Drug Permeability Assay.** Caco-2 cells were cultured for 21 days on polyethylene terephthalate membranes with 1.0 micron-pores using BD Biosciences 96-MultiWell Insert System. Under these culture conditions Caco-2 cells form a confluent barrier of polarized human intestinal enterocyte-like cells (Hidalgo et al., 1989). Compounds were dissolved in neat DMSO and diluted in the culture medium to final concentration of 20 μM, maintaining a 0.1% DMSO concentration. Apparent compound permeability (Papp x10⁻⁶ cm/sec) was evaluated by exposing the apical or basal surface of the cells and incubating in 10% FBS DMEM for 2 h at 37 ºC and 0.5% CO₂. Samples were collected and analyzed by LC-MS/MS.

**Inhibition of ApoB and Apo-A1 Secretion in Hepatocytes and Caco-2 Cells.** The cellular assays used to determine MTP inhibition (ApoB and ApoA1 secretion from primary hepatocytes and Caco-2 cells) were described by Chandler et al. (2003). Human hepatocytes were freshly harvested from male donors, pooled, plated in 96-well plates, cultured in collagen and matrigel sandwich, (CellzDirect or InVitroTech), and maintained in vendor’s specified culture media. Caco-2 cells were prepared as described in the aforementioned paragraph.

Compounds were dissolved in DMSO and serially diluted in the culture medium, maintaining a 0.1% DMSO concentration. Compounds were evaluated in both cell types (Caco-2 assay test compounds were evaluated by exposing the apical surface) by incubating in 10% FBS DMEM for 24 h at 37 ºC and 0.5% CO₂. Concentrations of ApoB and ApoA1 were determined from aliquots of culture media obtained from the basal sides of Caco-2 monolayers, using an ELISA kit (AlerCheck, Portland, ME).

**Studies Using Animals.** The Institutional Animal Care and Use Committee approved all procedures using experimental animals. Sprague-Dawley rats and ApoE⁻/⁻ mice were provided the indicated diets *ad libitum* unless otherwise stated and water was available *ad libitum*. Rats were treated by oral gavage at a

Page 9 of 39
volume of 5mL/kg body weight with an aqueous solution containing 0.4% methyl cellulose (MC) or an aqueous solution containing 0.4% MC plus MTP inhibitors. Mice were administered SLx-4090 by gavage (1 mL/kg body weight) or in high fat diet (HFD) or standard rodent chow/low fat diet (LFD). Animals on HFD were acclimated to the diet at least one week prior to initiating administration of SLx-4090 as a dietary supplement in the chow.

**Serum Chemistries.** For TG studies using rats, blood was collected via retro orbital bleeds at an approximate volume of 0.5 mL. No animal was bled on more than three occasions. For terminal studies, blood was collected via cardiac puncture in CO₂ anesthetized animals and placed into serum separating tubes to obtain serum. The serum was frozen on dry ice prior to shipment to IDEXX Laboratories (Sacramento, CA) for analyses of LDL-C, HDL-C cholesterol and TGs.

Analysis of serum FFA was performed using a commercially available kit (Zen-Bio, Inc., Research Triangle Park, NC).

**Postprandial Lipids Following Acute Lipid Challenge in Rats.** Male Sprague Dawley (200-250 g) were fasted overnight (ca. 14-18 hr), with water available *ad libitum*. The following morning blood samples were drawn for baseline TG determinations. The animals were dosed orally with SLx-4090 or reference compounds followed 20 minutes later by an oral gavage of a 1 mL of corn oil/sucrose mixture (320 mg corn oil and 430 mg sucrose per 1 mL). Control animals received vehicle and the corn oil/sucrose mixture. Blood samples were collected via retro orbital sinus at various time points for TG and PK measures. Approximately 0.5 mL of blood was drawn per time point per rat in a tube containing citric acid. The blood samples were stored on ice until they were spun via centrifugation to separate the plasma, which was stored at -80°C until analyzed.

**Duration of Action on Postprandial Lipid Response.** Male Sprague Dawley (200-250 g) were treated as described immediately above with the exception that administration of the corn oil/sucrose
mixture was delayed to 0, 2, 4, 6, 8, 20 or 24 hr following the administration of SLx-4090 (30 mg/kg) or vehicle.

**Determination of the Rates of Hepatic and Intestinal TG Secretion.** Tyloxapol (Triton WR1339) prevents the catabolism of TG-rich lipoproteins by serum lipases and allows a time dependent and linear increase in plasma TG levels. In the fasted state, where little to no intestinal chylomicron production, hepatic VLDL production is the predominant source of nascent plasma TG (Chandler et al., 2003). It is therefore possible to determine if SLx-4090 inhibits the production of liver VLDL by evaluating plasma TG accumulation over time. Male Sprague Dawley (200-250 g) were fasted overnight (ca. 14-18 hr), but allowed the access to water *ad libitum*. Tyloxapol (1.0 mL; 125 mg/mL) was administered intravenously 60 minutes after oral administration of MTP inhibitors. Approximately 0.5 mL of blood (retro orbital) was drawn per indicated time point per rat in a tube containing citric acid. The blood samples were stored on ice until they were spun down via centrifugation to separate the plasma, which was stored at -80°C prior to analysis.

**ApoE−/− Mice.** Three to four week old male apolipoprotein E deficient (ApoE−/−; B6.129-ApoEtm1UncN11) mice were purchased from Taconic Farms (Rockville, MD). Mice received LFD and water *ad libitum* and were acclimated to the environmentally and lighting (12 hr light/dark phases) controlled facility for 1-2 weeks. At five weeks of age, the mice were placed into one of six groups (n=7-8 / group). Two groups of mice received either the LFD diet (n=8) or the LFD diet containing 0.06% SLx-4090 (n=8, LFD-4090). The remaining mice received either the HFD diet (n=7, HFD, TD.88137, Harlan Laboratories, Madison, WI) or a HFD diet containing a low dose (n=7, HFD-LD, 0.006%), a middle dose (n=8, HFD-MD, 0.019% SLx-4090), or a high dose (n=8, HFD-HD, 0.06% SLx-4090) of the test article, *ad libitum*, for 10 weeks. Body weight and food consumption were recorded daily throughout the study. Estimated SLx-4090 dose was calculated based on food consumption per period, multiplied by the appropriate SLx-4090 concentration, divided by body weight. Following the 10 week treatment period, all
mice were terminated via CO₂ inhalation in the non-fasted state and liver and visceral (omentumal and epididymal) fat pads excised and weighed.

**Toxicological Evaluation of SLx-4090.** The effects of SLx-4090 administered once daily for 90 days was evaluated in male and female Sprague Dawley rats under contract to Bridge Pharmaceuticals as part of the GLP evaluation of the compound. Bridge Pharmaceuticals is an AALAC accredited facility. Briefly, animals were housed in single suspended cages under standard vivarium conditions and administered SLx-4090 at 40, 200 or 1000 mg/kg/day. At periodic intervals throughout the study body weight and food consumption was recorded and animals were observed for clinical signs of morbidity. Blood samples were collected from a separate cohort of animals for clinical chemistry panels and for PK analysis. Following 90 days of drug administration, the animals were euthanized using CO₂ inhalation and exsanguination. A full battery of organs was obtained for histological evaluation by hematoxylin and eosin staining.

**Effect of SLx-4090 on Serum Levels of Vitamins E, A and C.** Adult male Sprague-Dawley rats were dosed for 4 or 14 consecutive days with SLx-4090 or CP-346086 (PO, 30 mg/kg, 0.4 % MC). Animals were allowed access to standard laboratory chow and water throughout the dosing period and were euthanized without an overnight fast. On the morning of day 5 or 15, the animals were euthanized with CO₂ and approximately 5 mL of blood was collected via cardiac puncture into K₃EDTA containing vacutainer tubes. The samples were reduced to plasma and the levels of endogenous fat soluble vitamins E and A and water soluble vitamin C were determined via HPLC (Paulo et al., 1999).

**In vitro Metabolism of SLx-4090.** SLx-4090 (5 M) was incubated at 37 °C with human liver microsomes (0.4 mg/mL protein) in the presence and absence of reductase NADPH (8 mM). After 60 minutes the reaction was stopped by adding a 0.3% solution of acetic acid in acetonitrile containing internal standard (haloperidol; 1.67 M). The samples were diluted with water, centrifuged and the
resulting supernatants were analyzed for SLx-4090 and metabolites according to the LC-MS/MS method described below.

Pharmacokinetics (Systemic). Male Sprague Dawley rats previously implanted with jugular vein cannula were dosed orally by gavage (10 or 30 mg/kg; 0.4% MC; 10 mL/kg) or intravenously (1 mg/kg; 5% N-methyl-pyrrolidinone, 45% PEG400, 50% b-(2-hydroxypropyl)-cyclodextrin (20% in water); 1 mL/kg) with the indicated amount of SLx-4090. Animals were acclimated to the vivarium for at least 5 days prior to use. Food and water was available ad libitum except for an 8 – 10 hr fast prior to dosing. Food was returned to the animals ~ 1 hr postdose. Blood samples were collected (K₃EDTA) via implanted venous cannula at the indicated times postdose. The samples were reduced to plasma via centrifugation and stored frozen at -20°C until analyzed for SLx-4090 and SLx-4099 as described below.

Pharmacokinetics (Portal vein). Adult male Sprague Dawley rats previously implanted with portal vein cannula were obtained from Hilltop Laboratories and acclimated to vivarium conditions for a period of 3 days prior to use. Food and water was available ad libitum except for an 8 – 10 hr fast prior to dosing. Food was returned to the animals ~ 1 hr postdose. SLx-4090 (25 or 100 mg/kg) was administered via oral gavage (0.4% MC; 10 mL/kg) and blood samples (~0.5 mL) were collected into K₃EDTA at predose and 0.5, 1, 2, 4, 8, 12 and 24 hours postdose. The samples were reduced to plasma via centrifugation and stored frozen at -20°C until analyzed for SLx-4090 and SLx-4099 as described below.

MTP inhibitors were extracted from rat plasma by precipitation with acetonitrile in a 96 well Captiva filtration plate and quantitated using liquid chromatography in conjunction with mass spectrometry. Plasma (50 µL) was added to each well of the Captiva filtration plate followed by the acetonitrile (150 µL) containing 1.6 µM haloperidol (internal standard) and water (50 µL). The wells were sealed and the samples mixed by inverting the plate several times manually. The samples were then slowly filtered under vacuum and subsequently analyzed by LC-MS/MS.
**LC-MS/MS Analysis.** The LC-MS/MS system consisted of a binary pump, a plate autosampler with temperature control unit degasser and a 2000QTrap LC-MS/MS system (Applied Biosystems, Framingham, MA) fitted with Turbolonspray interface. Samples were chromatographed on an Xterra MS C_{18} 2.1x20 mm, 3.5 μm column (Waters, Milford, MA, P/N 186001923), using the fast mobile phase gradient (mobile phase A- 0.1% formic acid (FA) in MilliQ water (v/v); mobile phase B- 0.085% FA in acetonitrile (v/v)) with 1 min equilibration to aqueous phase. The flow rate was 1 mL/min, with 1:10 split before the ion source and the injection volume was 5 μL. The mass spectrometer was operated in the positive ion mode with a source temperature of 350°C, using nitrogen as nebulizing and heating gas. MS-MS analysis was carried out in the Selected Reaction Monitoring mode and the analytes were monitored using an appropriate the precursor-product ion pair. The LC-MS/MS data were calculated using the Analyst 1.4 quantitation software supplied by Applied Biosystems. Statistical analysis was employed to generate the means, standard deviations, coefficient of variation and regression parameters. The peak area ratio of the test item: internal standard was calculated for each sample. A calibration line was generated using the test item: internal standard area ratio plotted against the actual test item concentration to generate a standard calibration line. The typical assay range was from 5 nM to 10 μM while the LOQ for the assay was found to be 5 ng/mL (equivalent to ~10 nM).

**Data Analysis.** Statistical analyses were performed using GraphPad Prism V4. Inhibition constants or ED_{50} values were calculated using the variable slope sigmoidal model. Group mean analyses were performed using a one way ANOVA with Tukey’s post-hoc test to determine the significance of differences among groups. Comparisons between two groups were made using Student's two-tailed t-test with or without Welch's correction for uneven variance.
RESULTS

**Inhibition of MTP-mediated lipid transfer.** Incubation of MTP isolated from human liver microsomes and donor vesicles containing quenched fluorescent lipids with varying concentrations of MTP inhibitors resulted in a concentration dependent inhibition of MTP-mediated TG transfer between vesicles (see Table 1). The IC$_{50}$ value for the selective inhibitor of MTP, CP-346086 (2.0 nM) was consistent with previously published findings (Chandler et al., 2003; Li et al., 2007). The IC$_{50}$ values obtained for the tetrahydroisoquinoline derivatives SLx-4090 and SLx-4099 (M1 metabolite of SLx-4090) (Figure 1A) were determined to be 8.0 ± 0.8 and 262 ± 30 nM, respectively. Data for SLx-4090 and SLx-4099 inhibition of MTP-mediated lipid transfer are shown in Figure 1B.

**Inhibition of ApoB and ApoA1 secretion from human primary hepatocytes and Caco-2 cells.** SLx-4090 was a potent inhibitor of ApoB secretion in primary human hepatocytes and Caco-2 cells (Table 1). In contrast, SLx-4099, the primary metabolite of SLx-4090, was 33- and 55-fold less active than the parent molecule in primary human hepatocytes and Caco-2 cells, respectively. Neither SLx-4090 nor SLx-4099 inhibited the secretion of ApoA1 at the highest concentration tested (30 µM) demonstrating the specificity of SLx-4090 for MTP-mediated events.

**Permeability of Caco-2 Cells to MTP Inhibitors.** SLx-4090 and the reference inhibitor CP-346086were evaluated for both apical to basal (A to B) transport as well as basal to apical (B to A) transport. As expected, CP-346086 was permeable in this model as determined by its high apparent drug permeability coefficient $P_{\text{app}} \sim 14x10^{-6}$ cm/sec (Table 1) consistent with the oral bioavailability of this drug. SLx-4090 was designed to selectively accumulate in the apical plasma membrane of the enterocyte and consistent with this strategy was not permeable in the human Caco-2 cell assay. The M1 metabolite of SLx-4090, SLx-4099, displayed no A to B permeability, but a small B to A permeability was detected.

**Effect of SLx-4090 on postprandial triglycerides and free fatty acids.** Oral gavage of SLx-4090 to male Sprague Dawley rats resulted in a dose dependent reduction of PP serum TG increases (Figure
2A). The estimated ED₅₀ values for SLx-4090 (the dose reducing postprandial TG increases by 50%) was approximately 7 mg/kg (Figure 2B). The action was rapid in onset, being apparent when animals were challenged with a corn oil/sugar gavage within 1 hr of compound administration, and was dose-dependent (Figure 2C). In contrast to SLx-4090, CP-346086 showed a trend in lowering TG levels below predose baseline.

The serum TG lowering effects of SLx-4090 were long lasting. Following administration of 30 mg/kg SLx-4090 significantly inhibited the PP spike in serum TGs for up to 6 hours. A non-significant trend toward lowering serum TGs levels relative to the vehicle control was observed for up to 20 hours (Figure 2D).

In contrast to the effects of CP-346086 which inhibits both enterocytic and hepatic MTP, SLx-4090 did not result in a decrease in serum TG levels below baseline levels (Figure 2C). Total serum TG pools are a combined response to both enterocyte TG absorption and hepatic TG release. Compounds which inhibit only one of these pools would not be expected to completely block the PP TG rise which is mediated by both sources of lipid. The finding is consistent with the suggestion that SLx-4090 acts at the level of the enterocyte. Both SLx-4090 and CP-346086 inhibited the PP increase in serum free fatty acids (Figure 2E).

**Enterocyte specific action of SLx-4090.** In fasted animals serum TG levels are predominantly of hepatic origin with little or no TG being secreted by the intestine. Tyloxapol treated groups showed a linear increase in serum TGs over several hours reflecting a baseline rate of hepatic TG secretion (Figure 3). SLx-4090 (30 mg/kg) did not impact TG levels in tyloxapol treated animals suggesting that it does not inhibit hepatic MTP. CP-346086, a systemically available MTP inhibitor, completely blocked the secretion serum TGs from the liver (Figure 3). These results indicate that SLx-4090 was not active in the liver, and are consistent with the acute PP TG data indicating that SLx-4090 is a non-systemically available compound that retains enterocytic MTP inhibitory activity.
**Effects of SLx-4090 on body weight, food consumption and serum lipid measures in ApoE<sup>−/−</sup> mice.** To further evaluate the effects of SLx-4090 on metabolic status SLx-4090 was administered as an admix in a HFD or LFD for 10 weeks to ApoE<sup>−/−</sup> mice (Table 2). In the apolipoprotein E deficient (ApoE<sup>−/−</sup>) mouse, a well-known dyslipidemic animal model, the severity of the hyperlipidemia is exacerbated by high dietary fat.

Body weights were similar among all groups at the start of the treatment period. Based on food consumption measures and body weight records the average daily dose of SLx-4090 was 94 mg/kg/day for animals maintained on the LFD. In the 3 dose groups maintained on HFD, the average daily dose of SLx-4090 was 5.8 (low dose HFD), 18.9 (mid dose HFD), and 66.8 (high dose HFD) mg/kg/day, respectively, during the 10 week treatment period.

At the end of treatment, LFD-4090 mice had similar weight gain and food consumption as control LFD mice (Table 2). Both the high and mid dose HFD-SLx-4090 treatment groups had significantly reduced weight gain compared to control animals fed the HFD alone, or the HFD and the lowest dose of SLx-4090 (Table 2). The reduced weight gain during SLx-4090 treatment occurred despite similar per day food consumption among all treatment groups.

Visceral fat weight, normalized to body weight, was significantly reduced by the middle (38.9±7.2 mg fat/g BW; p<0.05) and high dose (27.2±4.4 mg/g; p<0.01) SLx-4090 treatment compared to control HFD diet and low dose SLx-4090 animals (58.4±2.6 mg/g) (Figure 4). HFD mice administered the lowest dose of SLx-4090 had similar visceral fat-body weight ratio as control HFD animals.

Serum TG levels were similar between LFD and LFD-SLx-4090 mice. In contrast, both mid and high dose SLx-4090 treatment in HFD fed mice significantly reduced serum TGs mice compared to control HFD mice (Figure 5).

SLx-4090 treatment altered cholesterol homeostasis in both LFD and HFD fed mice (Figure 6). LFD-4090 mice had significant reduction of 22% and 26% (both p<0.01) in total and LDL cholesterol levels.
and a significant increase of 14% (p<0.05) in HDL-C levels compared to control LFD mice. In HFD fed mice, the mid dose and high dose mice had significantly decreased total cholesterol (-41%, p<0.01, and -68%, p<0.001, respectively) and LDL-C (-42%, p<0.01, and -70%, p<0.001, respectively) and significantly increased HDL-C (+67%, p<0.01 and +123%, p<0.001, respectively) compared to control HFD mice. Low dose HFD mice had similar total and LDL cholesterol as control HFD, but had a significant increase in HDL cholesterol (+37%, p<0.05).

**Toxicology.** SLx-4090, when administered via oral gavage once daily for 90 consecutive days to male and female Sprague Dawley rats at doses of 40, 200 and 1000 mg/kg/day, resulted in no mortality, or adverse findings for clinical or cageside observations, body weights, body weight changes, food consumption, clinical pathology, gross pathology or histopathology The no-observed-adverse-effect-level (NOAEL) was at least 1000 mg/kg in male and female rats (Sweetnam, unpublished data).

**Effects on Serum Vitamin Levels.** In animals fed a standard diet with no additional vitamin supplementation SLx-4090 or CP-346086 (30 mg/kg) administered for 4 or 14 days had no effect on endogenous levels of vitamin A (Table 3). There was no effect of 4 days drug administration on vitamin E, and a marginal but non significant 24 % decrease in mean circulating levels of this vitamin following 14 days SLx-4090 administration. Both 4 and 14 day administration of CP-346086 resulted in a greater (-26 % and -46 %, respectively) decrease in vitamin E. However, this effect was not statistically significant. Short term administration of either compound had no effect on the water soluble vitamin C.

**In vitro Metabolism in Human Liver Microsomes**

The *in vitro* half life of SLx-4090 was determined using a commercial preparation of human liver microsomes. Reactions were carried out for 60 minutes in the presence and absence of reductase NADPH. Samples were assayed for parent compound and metabolites using LC-MS/MS methods. The results demonstrated a rapid metabolism of SLx-4090 to SLx-4099 (see Figure 1) in the presence of NADPH with a SLx-4090 half-life of approximately 8 minutes. Microsomal reaction of SLx-4090 in the
absence of reductase NADPH failed to produce metabolite SLX-4099 indicating that it is exclusively formed via cytochrome P450 oxidative metabolism. In similar studies using rat and dog hepatic or intestinal microsomes, only SLX-4099 has been identified as a metabolic product suggesting the metabolic fate of SLX-4090 is similar in all species (data not shown).

**Pharmacokinetics (Systemic).** The intrinsic PK of SLX-4090 in rats determined via intravenous drug administration is shown in Figure 7. Following intravenous administration of SLX-4090 (1 mg/kg) significant levels of SLX-4090 were evident at the first time point (5 min). Levels of SLX-4090 rapidly declined such that they were less than 50 ng/mL by the 2 hour time point. The $t_{1/2}$ value for SLX-4090 following intravenous dosing was 1.60 hr. Substantially lesser amounts of SLX-4099 were detected in these animals.

When dosed orally at 10 mg/kg, no detectable amounts of SLX-4090 or its metabolite, SLX-4099 were found at any time point up to 24 hrs post dose (lower limit of quantitation LOQ = 5 ng/mL). The oral bioavailability following a single oral dose of 10 mg/kg was 0%. When dosed orally at 30 mg/kg, plasma samples from five of the six rats showed no quantifiable amounts of SLX-4090 or its metabolite, SLX-4099. One animal in this group showed an amount of SLX-4090 slightly above the LOQ at one time point although no SLX-4099 was detected. The oral bioavailability following a single oral dose of 30 mg/kg was calculated to be 0.0011%. These data indicate that the absolute oral bioavailability of SLX-4090 following single pharmacologically relevant doses of 10 and 30 mg/kg is effectively 0%.

**Pharmacokinetics (Portal Vein).** When blood was collected from the portal vein of animals dosed orally with 25 mg/kg SLX-4090 no SLX-4090 was detected in portal vein plasma up to 24 hr postdose. In 3 of 4 animals evaluated no levels of the metabolite SLX-4099 could be quantified up to 24 hr post dose. In the fourth animal a small amount of SLX-4099 (12.6 ng/ml) was seen at a single timepoint (12 hr). Following oral gavage of 100 mg/kg SLX-4090, no levels of SLX-4090 or SLX-4099 could be quantified in rat plasma from blood drawn from the portal vein up to 24 hr post dose in any of the four animals.
studied. These data indicate that the absorption of SLx-4090 following doses of 25 and 100 mg/kg is extremely low with no SLx-4090 detected in the portal circulation.
DISCUSSION

The enterocyte, which lines the luminal wall of the intestine, has an expansive apical surface area and the intracellular machinery needed to produce lipoprotein vesicles that pass through the basal surface and into systemic circulation. This unique design optimizes the transfer of dietary nutrients into circulation (Mansbach and Siddiqi, 2010). One of the key players in the formation of lipoprotein vesicles or “chylomicrons” is MTP making it a seemingly ideal target to disrupt dietary contributions to systemic lipid and cholesterol loads (Wierzbicki et al., 2009). Unfortunately MTP is also found in a number of additional organs with notably high levels in the liver, retina and heart (Boren et al., 2010; Li et al., 2005). Inhibition of hepatic MTP decreases the ability of the liver to rid itself of fat and chronic treatment with first generation MTP inhibitors resulted in unacceptable rises in liver transaminases and hepatic steatosis in rodent models and in man (Lilly and Rader, 2007; Miyazaki et al., 2007; Wren et al., 2007; Lammens et al., 1999). Inhibition of MTP in the heart and in the retina may also elicit adverse effects (Boren et al., 2010; Li et al., 2005). The development of small molecule therapeutics that selectively target the enterocyte but do not impact the lipid metabolism in organs such as the liver could provide a novel strategy to develop new therapies for the treatment of metabolic diseases. If these agents were efficacious they could provide a margin of safety superior to currently available drugs used in the treatment of metabolic disease. Based on this hypothesis a strategy was implemented to develop an MTP inhibitor that was available to the intracellular space of the enterocyte (enterocytic availability) but did not enter the systemic circulation (non-bioavailability). Intestinal and hepatic MTP are highly conserved making the development of an enterocytic selective compound a pharmacokinetic rather than a pharmacodynamic strategy.

SLx-4090 is an inhibitor of MTP that preferentially accumulates within the enterocyte and effectively blocks the formation of chylomicrons in vitro and in vivo. For example, in mass balance/tissue distribution studies with [14C]SLx-4090 approximately 10% of the administered dose is recovered within
the small intestine whereas less than 1% is recovered from all other tissues (data not shown). Our studies establish that SLx-4090 preferentially inhibits enterocytic MTP resulting in the improvement of metabolic endpoints and lacks the hepatic toxicities associated with systemically available MTP inhibitors.

SLx-4090 is a potent and selective inhibitor of MTP activity as demonstrated in human hepatic microsomal preparations and was comparable in potency to the clinical reference agents CP-346086 (Chandler et al., 2003). At the cellular level SLx-4090 was equipotent to CP-346086 in the inhibition of ApoB secretion from primary human hepatocytes and, like CP-346086, had no effect on the non-MTP-mediated secretion of ApoA1. The latter is significant since ApoB but not ApoA1 requires the activity of MTP for lipoprotein vesicle formation. SLx-4099, the principal metabolite of SLx-4090, was significantly less potent than SLx-4090 at inhibiting MTP, at the molecular and cellular level.

To confirm the enterocytic selectivity of SLx-4090 a series of in vitro and in vivo studies were performed. Data obtained using the differentiated Caco-2 cell permeability model were consistent with the idea that SLx-4090 would have limited systemic availability when dosed orally. SLx-4090 did not transit through the Caco-2 cell barrier when applied to either the apical or basal cell surface. While these data suggested that SLx-4090 would have limited systemic availability they did not demonstrate the enterocytic availability of the SLx-4090. The ability of SLx-4090 to inhibit the secretion of ApoB from the Caco-2 cells (Table 1) is consistent with the notion that SLx-4090 is capable of entering the enterocyte and inhibiting MTP found within. It should be noted that other drugs (eg, ezetimide) which inhibit cholesterol absorption (Van Heek et al, 1997) do not alter Apo-B secretion kinetics (Tremblay et al., 2006) and suggesting that this site of action is not responsible for the actions noted for SLx-4090.

The systemic absorption of SLx-4090 is limited by its conversion to SLx-4099 by cytochrome P450 enzymes located in the enterocytes. This metabolism, as well as the natural turnover of the enterocytes from the intestinal lining (Thomson et al. 1994), limits the systemic absorption of SLx-4090.
Initial PK (LOQ 5 ng/mL) revealed that single doses (≤ 30 mg/kg) of SLx-4090 had an absolute bioavailability of 0% and that the major metabolite SLx-4099 could not be detected in serum. It remained possible however that SLx-4090 was absorbed and transported via the portal vein to the liver where it might undergo first pass metabolism. When SLx-4090 was dosed orally up to 100 mg/kg, neither SLx-4090 nor SLx-4099 were detected in plasma obtained from portal vein cannulated animals. These data is consistent with the lack of absorption of SLx-4090 from the gut and absence of SLx-4090 exposure to the liver.

To determine if SLx-4090 was enterocytically available after oral administration, rats were challenged with a bolus of corn oil/sucrose and levels of PP TGs and free fatty acids were determined. SLx-4090 dose dependently inhibited the rise in PP lipids, but did not result in a lowering of serum lipids below baseline levels. The effect was long lasting with a maximally efficacious dose (30 mg/kg) resulting in a decrease in meal driven serum lipid levels for 6 hours. In contrast to SLx-4090 the systemically available MTP inhibitor CP-346086 appeared to reduce lipids to below baseline levels. Serum lipid levels represent the sum of lipids contributed by multiple sources including those derived from dietary intake and those released from tissue sources, principally the liver. The response to MTP inhibitors acting at both the enterocyte and the liver are typically characterized by a decrease in serum lipids to levels below the predose fasting baseline. SLx-4090, acting only at the level of the enterocyte, affects only that portion of the serum lipid burden arising from dietary sources and does not lower baseline TG following a single dose. Finally, SLx-4090 administered at 30 mg/kg significantly inhibited the raise of PP FFAs, similar to CP-346086. This suggests that dietary lipids broken down in the intestinal lumen by lipases are not transported into the systemic circulation by a non-MTP mediated mechanism.

To further demonstrate the enterocytic specificity of SLx-4090, animals were treated with the serum lipase inhibitor tyloxapol. When fasted overnight the contribution of dietary lipids to the total serum lipid
load is negligible. Under these conditions and in the presence of tyloxapol, the release of lipids from hepatic stores results in an increase in serum lipids. In the presence of tyloxapol, and the absence of dietary lipids, the rate of serum lipid increase is a direct reflection of the rate of hepatic lipid release. Consistent with an enterocytic site of action, SLx-4090 did not change the rate of serum lipid accumulation in these experiments. The systemically active MTP inhibitor CP-346086 blunted the increase in serum lipids as predicted by the inhibition of hepatic MTP.

Experimental studies have demonstrated that MTP inhibition leads to reductions in circulating lipids. Systemic MTP inhibitors have been shown to reduce TG and cholesterol in normal rodents and humans (Lilly and Rader, 2007; Miyazaki et al., 2007; Aggarwal et al., 2005; Chandler et al., 2003), in HFD ApoE<sup>−/−</sup> (Ueshima et al., 2005) and in mice with intestinal-specific MTP deletion (Xie et al., 2006). ApoE<sup>−/−</sup> mice maintained on a HFD and SLx-4090 for 10 weeks had improved lipid profiles (lower baseline TG, total cholesterol and LDL-C while raising HDL-C levels) as compared to vehicle treated animals. In addition, SLx-4090 decreased the body weight gain in ApoE<sup>−/−</sup> mice over the course of treatment and had a positive impact on liver and fat stores as evidenced by reductions in fat and liver weight to body weight ratios. The overall reduction in body weight as compared to vehicle animals was not the result of a decrease in food intake that has been reported for the MTP inhibitor dirlotapide (Wren et al., 2007). The enterocytic selectivity of SLx-4090 was further supported by the lack of elevation of the liver transaminases even at the highest dose tested. In contrast, the systemic MTP inhibitor implitapide significantly elevated liver transaminases in these mice (Sweetnam, unpublished data). Unlike other MTP inhibitors (Ueshima et al., 2005; Chandler et al., 2003, Miyazaki et al., 2007), SLx-4090 also significantly increased HDL-C.

The major impediment to the development of clinically useful MTP inhibitors has been the rapid development of liver toxicities (Lilly and Rader, 2007, Miyazaki et al., 2007; Lammens et al., 1999). In contrast, SLx-4090 demonstrated no indication of hepatic damage from either a histological or a clinical
chemistry perspective in toxicological studies as long as 90 days with doses as high as 1000 mg/kg (rat) or 100 mg/kg (dog) (Sweetnam, unpublished data). These findings extended to all organ systems. The resistance of animals to hepatic damage is attributed to two primary characteristics of SLx-4090, its low absorption and rapid metabolism to SLx-4099, a compound with low potency to inhibit MTP.

SLx-4090 had only a minor, if any, impact on the levels of endogenous fat soluble vitamins, in contrast to other MPT inhibitors (Anwar et al., 2007). As blockade of essential nutrient absorption could be of concern in a chronic dosing scenario these data suggest that impact of SLx-4090 will be negligible in this regard.

Current dyslipidemic agents work predominantly by targeting the liver. The statins inhibit HMG-CoA reductase, while the fibrates target PPARalpha. Ezetimibe, a cholesterol absorption inhibitor thought to demonstrate the utility of targeting the absorption of cholesterol by the enterocyte has recently been shown to in part work through blocking the same uptake site in the liver. The combination of SLx-4090 with any of these agents presents a co-therapy strategy which would target two organs important in fat metabolism, the intestine and the liver. In addition, the reduction of circulating chylomicrons should ultimately reduce the number of circulating chylomicron remnants, reducing the risk of atherosclerotic plaque formation (Botham, 2008). The enterocytic lining of the intestinal lumen sits at the vertex of a host of metabolic diseases that are caused or exacerbated by improper dietary behaviors common in today’s society. For anatomical reasons, this tissue is an easily accessible target for therapies that reduce the passage of dietary lipid and cholesterol. This approach provides a direct method to induce caloric restriction and improve metabolic endpoints. Importantly, it is a strategy that does not involve the direct interaction with the liver and the complications that are often associated with doing so. This approach opens the way to look at other mechanisms to treat not only metabolic disorders but inflammation and potential cancers of the gastrointestinal tract.
ACKNOWLEDGEMENTS

The authors would like to acknowledge Drs. Maura Charlton, Warwick Tong, and William Prince for useful discussions. We also thank Bridge Global Pharmaceuticals for their efforts in executing the GLP toxicological study described within this report.
AUTHORSHIP CONTRIBUTIONS

Participated in research design: Kim, Wong, Cole, Kuo, Ellis, Ferkany, Sweetnam

Conducted experiments: Kim, Wong, Kuo

Contributed new reagents or analytical tools: Kim, Campbell, Schueller,

Performed data analysis: Kim, Wong, Kuo, Ellis, Ferkany, Sweetnam

Wrote or contributed to the writing of the manuscript: Schueller, Cole, Kuo, Ferkany, Sweetnam

Other: N/A
REFERENCES


*Atherosclerosis* **144** S1: 39.


FOOTNOTES

Financial Support: All of the studies reported in this article were supported by the corporate funds of Surface Logix, Inc. a privately held pharmaceutical company. All of the authors for this manuscript are (were) full time employees of Surface Logix at the time their contribution was completed.
LEGENDS FOR FIGURES

Figure 1. Structure and Activity of SLx-4090 and its principal metabolite, SLx-4099. (A) SLx-4090 is a free base. SLx-4099 is the desmethyl product of SLx-4090. (B) Inhibition of MTP-mediated lipid transfer by SLx-4090 and SLx-4099. MTP isolated from human liver microsomes was incubated with commercially available small unilamellar donor vesicles containing quenched fluorescent lipids and acceptor vesicles as described in Methods. The data are the mean ± SEM of six replicates.

Figure 2. Inhibition of PP serum lipid increases by SLx-4090; dose response and duration of action. (A) SLx-4090 was administered 20 min prior to the oral gavage of a corn oil/sucrose challenge. Blood samples were drawn at the indicated times for determination of serum TG levels. (B) The ED_{50} value for SLx-4090 to inhibit PP serum TG increases was calculated using the t=4hr data from Figure 2A and was estimated to be 7 mg/kg. (C) Animals were treated with SLx-4090 (30 mg/kg), the systemically active MTP inhibitor CP-346086 (30 mg/kg) or vehicle and challenged 20 min later with a corn oil/sucrose meal (*, p < 0.05 to vehicle, with the exception of CP-346086 where both replicates for n = 2 have been plotted). (D) SLx-4090 (30 mg/kg) was administered via oral gavage and followed by a corn oil/sucrose challenge at 0, 2, 4, 6, 8 or 20 hr following drug administration (*, p ≤ 0.03). (E) Utilizing dosing regimen identical to (D) serum free fatty acids were determined at the indicated times postdose. Values are the mean ± SEM of three to five separate determinations at each time point (*, p < 0.05; ++, p < 0.01; #, p < 0.01 for CP-346086 only).

Figure 3. Effect of tyloxapol on serum TGs levels following SLx-4090 or CP-346086 administration to rats. Rats were fasted overnight and administered tyloxapol (1.0 mL; 125 mg/mL; iv) and vehicle, SLx-4090 (30 mg/kg) or CP-346086 (30 mg/kg). Serum TGs (without any meal challenge) were determined at the indicated time following drug administration. Tyloxapol inhibits serum lipases. In the absence of a dietary source of TGs, the serum increase in TGs...
reflects the release of TGs from hepatic stores. Values are the mean ± SEM of three to five separate determinations at each time point (*, p < 0.05; **, p < 0.0001).

Figure 4. Visceral fat and liver weights adjusted for body weight in control and SLx-4090 treated ApoE<sup>−/−</sup> mice during low or high fat diet. Visceral fat pads were obtained from control HFD fed (HFD, n=7) ApoE<sup>−/−</sup> mice, and from mice ingesting HFD containing the low (LD, n=7), middle (MD, n=8 fat, n=7 liver), or high (HD, n=8) dose SLx-4090 at 10 weeks and normalized to terminal body weight. Livers were obtained from control LF fed (LFD, n=8) and SLx-4090 treated LF fed ApoE<sup>−/−</sup> mice (LF-4090, n=8) and from HFD mice ingesting the control HFD (n=7) or low dose (LD, n=7), mid dose (MD, n=8 fat, n=7 liver), or high dose (HD, n=8) dose SLx-4090 at 10 weeks and normalized to terminal body weight (* = p<0.05 vs HFD, ** = p<0.01 vs HFD).

Figure 5. Triglyceride levels in control and SLx-4090 treated ApoE<sup>−/−</sup> mice during low or high fat diet. Serum TG levels were obtained from control LFD fed (n=8) and SLx-4090 treated LFD fed ApoE<sup>−/−</sup> mice (LF-4090, n=8) and from HFD mice ingesting the control HFD (n=7) or low (LD, n=7), middle (MD, n=8 fat, n=7 liver), or high (HD, n=8) dose SLx-4090 at 10 weeks ( ** = p<0.01 vs HFD, *** = p<0.01 vs HFD).

Figure 6. Total, LDL, and HDL cholesterol levels in control and SLx-4090 treated ApoE<sup>−/−</sup> mice during low or high fat diet. Total, LDL, and HDL serum cholesterol levels were obtained from control LF fed (LFD, n=8) and SLx-4090 treated LFD fed ApoE<sup>−/−</sup> mice (LF-4090, n=8) and from HFD mice ingesting the control HFD (n=7) or low (LD, n=7), middle (MD, n=8 fat, n=7 liver), or high (HD, n=8) dose SLx-4090 at 10 weeks ( # = p<0.05 vs LFD, ## = p<0.01 vs LFD, * = p<0.05 vs HFD, ** = p<0.01 vs HFD, *** = p<0.01 vs HFD).

Figure 7. Intrinsic pharmacokinetics of SLx-4090 and SLx-4099 following intravenous administration to rats. Shown is the pharmacokinetic profile of SLx-4090 and its principal metabolite, SLx-4099, following intravenous administration of 1 mg/kg to male Sprague Dawley rats. Values are the mean ± SEM of at least 3 separate determinations at each time point.
**TABLES**

**Table 1  Biochemical Characterization of Inhibition of SLx-4090 and Its M1 Metabolite SLx-4099 and CP-346086, a MTP Inhibitor Reference Compound**

<table>
<thead>
<tr>
<th>Compound</th>
<th>Assay Type</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>MTP-mediated Lipid Transfer*</td>
<td>SLx-4090</td>
<td>8.0 ± 0.8 (3)</td>
</tr>
<tr>
<td></td>
<td>SLx-4099</td>
<td>262 ± 30 (3)</td>
</tr>
<tr>
<td></td>
<td>CP-346086</td>
<td>2.0</td>
</tr>
<tr>
<td>ApoB Secretion (Primary Hepatocytes)*</td>
<td>SLx-4090</td>
<td>81 ± 15 (5)</td>
</tr>
<tr>
<td></td>
<td>SLx-4099</td>
<td>2720 ± 490 (5)</td>
</tr>
<tr>
<td></td>
<td>CP-346086</td>
<td>N.D.</td>
</tr>
<tr>
<td>ApoB Secretion (Caco-2 cells)*</td>
<td>SLx-4090</td>
<td>9.6 ± 1.6 (5)</td>
</tr>
<tr>
<td></td>
<td>SLx-4099</td>
<td>530 ± 50 (5)</td>
</tr>
<tr>
<td></td>
<td>CP-346086</td>
<td>10</td>
</tr>
<tr>
<td>ApoA1 Secretion (Primary Hepatocytes or Caco-2)#</td>
<td>SLx-4090</td>
<td>&gt;30,000</td>
</tr>
<tr>
<td></td>
<td>SLx-4099</td>
<td>&gt;30,000</td>
</tr>
<tr>
<td></td>
<td>CP-346086</td>
<td>&gt;30,000</td>
</tr>
<tr>
<td>Caco-2 drug Permeability (Apical to Basal) **</td>
<td>SLx-4090</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>SLx-4099</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>CP-346086</td>
<td>14</td>
</tr>
<tr>
<td>Caco-2 Compound Permeability (Basal to Apical) **</td>
<td>SLx-4090</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>SLx-4099</td>
<td>1.01</td>
</tr>
<tr>
<td></td>
<td>CP-346086</td>
<td>12</td>
</tr>
</tbody>
</table>

*IC50 nM ± SEM (N)

**Papp x 10^-6 cm/sec

# Highest concentration tested

N.D. – not determined
Table 2. Body Weight and Food Intake in Control and SLx-4090 Treated ApoE<sup>−/−</sup> During Low or High Fat Diet

<table>
<thead>
<tr>
<th>Treatment (n)</th>
<th>Body Weight (Mean ± S.E.M; grams)</th>
<th>Food Consumption (grams)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Initial</td>
<td>Final</td>
</tr>
<tr>
<td>LFD (8)</td>
<td>21.1 ± 0.6</td>
<td>30.3 ± 0.9</td>
</tr>
<tr>
<td>LFD-4090 (8)</td>
<td>22.0 ± 0.4</td>
<td>30.0 ± 0.7</td>
</tr>
<tr>
<td>HFD (7)</td>
<td>22.0 ± 0.7</td>
<td>39.1 ± 1.7</td>
</tr>
<tr>
<td>HFD-LD (7)</td>
<td>22.1 ± 0.5</td>
<td>38.2 ± 1.8</td>
</tr>
<tr>
<td>HFD-MD (8)</td>
<td>21.5 ± 0.4</td>
<td>33.4 ± 1.0*</td>
</tr>
<tr>
<td>HFD-HD (8)</td>
<td>21.4 ± 0.4</td>
<td>31.3 ± 1.3**</td>
</tr>
</tbody>
</table>

Food consumption represents the mean food consumption for all animals in a single cage, individual animal food consumption was not determined as the animals were group housed.

HFD-LD = SLx-4090 5.8 mg/kg/day
HFD-MD = SLx-4090 18.9 mg/kg/day
HFD-HD = SLx-4090 66.8 mg/kg/day

* = p<0.05 vs HFD, ** = p<0.01 vs HFD, *** = p<0.001 vs HFD
Table 3  Effect of SLx-4090 on Serum Levels of Vitamins E, A and C in Male Sprague-Dawley Rats

<table>
<thead>
<tr>
<th>Dose Regimen</th>
<th>4 daily doses</th>
<th>14 daily doses</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Vehicle</td>
<td>SLx-4090 (30 mg/kg)</td>
</tr>
<tr>
<td>Vitamin E</td>
<td>1.27 ± 0.17 (4)</td>
<td>1.49 ± 0.16 (5)</td>
</tr>
<tr>
<td>Vitamin A</td>
<td>0.76 ± 0.09 (4)</td>
<td>0.76 ± 0.05 (5)</td>
</tr>
<tr>
<td>Vitamin C</td>
<td>2.73 ± 0.34 (5)</td>
<td>2.78 ± 0.25 (5)</td>
</tr>
</tbody>
</table>

Values are the mean ± SEM of the number of animals shown in parentheses and are reported as µg/mL.

There were no significant differences among groups or treatments on any measure.
Figure 1

A. SLx-4090

B. Log (SLx-4090) [M]

IC$_{50}$ = 0 ± 0.8 nM

B. Log (SLx-4099) [M]

IC$_{50}$ = 260 ± 30 nM
Figure 2

A. % Change from Baseline vs. Time Postdose (hr)

B. % Inhibition vs. Log₁₀ [SLx-4090] (mg/kg)

C. Triglycerides (mg/dL) vs. Time Postdose (hr)

D. % Delta Baseline vs. Time Postdose (hr)

E. Serum Free Fatty Acid (μM) vs. Time Postdose (hr)

ED₅₀ = 7.0 mg/kg
Figure 3

This article has not been copyedited and formatted. The final version may differ from this version.
Figure 4

- **Visceral Fat-Body Weight Ratio (mg/g)**
  - LFD
  - LFD-4090
  - HFD
  - HFD-MD
  - HFD-LD
  - HFD-HD

- **Liver-Body Weight Ratio (mg/g)**
  - LFD
  - LFD-4090
  - HFD
  - HFD-MD
  - HFD-LD
  - HFD-HD

* and ** indicate significant differences.
Figure 5

Serum Triglyceride (mg/dL)

HFD     HFD-LD     HFD-MD     HFD-HD

LFD     LFD-4090

**     ***
Figure 6

Serum Cholesterol (mg/dL)

Serum LDL Cholesterol (mg/dL)

Serum HDL Cholesterol (mg/dL)

LFD  LFD-4090  HFD  HFD-LD  HFD-MD  HFD-HD

This article has not been copyedited and formatted. The final version may differ from this version.
Figure 7

- SLx-4090 (1 mg/kg i.v.)
- SLx-4099 (from 1 mg/kg 4090 i.v.)